Business Sweden Sweden

Business Sweden helps global companies to establish business and research activities in Sweden. We provide advice, information and support free of charge and in full confidentiality. Our industry experts can connect you with the right business and investment opportunities, being the best partner when investing in Sweden.

Hampus Nilzen
Senior Investment Advisor 

Chinese University of Hong Kong Hong Kong SAR China

As one of the top universities in Asia-Pacific, The Chinese University of Hong Kong (CUHK) is committed to knowledge transfer and seeks to foster partnerships to commercialise our university’s technologies in the best way to benefit both industry and society. In this regard, CUHK is continuously looking for potential partners/licensees in our below areas of biomedical technologies:

 

(1)   Therapeutics: Digestive Cancer / Diabetes / Liver Cancer / Neurological Disorders / Orthopaedic and Traumatological Disorders / Pluripotent Stem Cells (see https://goo.gl/Ozm5Gz)

(2)   Diagnostics: Cardiovascular Disorders / Digestive Cancers / Diabetes & its Comorbidities / Gynecology and Obstetrics / Orthopaedic & Traumatological Disorders / Wearables (see https://goo.gl/gcbdLF)

(3) Robotics: Surgical Robots / Endoscopes for Minimally Invasive Surgery and Diagnostic Purposes (see https://goo.gl/TrQSrz

Dr. Ken YC Chow
Dr. Ken YC Chow
Technology Liaison Officer 
BIO

Prof. Edwin CHAN from the School Life Sciences from the Chinese University of Hong Kong is working on rare neurodegenerative diseases including the Huntington’s Disease (HD). He recently developed a new inhibitor for the treatment of HD. This patented technology is known as P3. P3 is a 13-amino acid peptidylic inhibitor that can potently suppress expanded Polyglutamine (PolyQ) / CAG RNA-induced nucleolar stress, and rescue neurodegeneration in animal disease model and cell death in patient fibroblasts.

 

The core benefits of this technology are:

(1)   the inhibitor is capable of directly interacting with and neutralizing the toxic expanded PolyQ / CAG RNA,

(2)   the mechanism of this inhibitor is well-defined that it reduces cellular p53 level and suppresses caspase activities, and

(3)   with proven potential to treat other polyglutamine diseases, such as spinocerebellar ataxias (SCA).

 

Related patent and references:

(1)   Zhang et al, Dis. Model. Mech, 2016 (http://www.ncbi.nlm.nih.gov/pubmed/26839389)

(2)   Tsoi et al, PNAS, 2012 (http://www.ncbi.nlm.nih.gov/pubmed/22847428)

(3)   US9,297,798 (http://www.google.com/patents/US9297798)

(4)   US Provisional patent (Priority date: 23 Dec 2015)

(5)   US non-Provisional patent (Priority date: 17 Feb 2016)

 

More details:

(1)   Introduction Slides: http://goo.gl/RSZf7g

(2)   Introduction Brochure: http://goo.gl/IdbVRG

(3)  Introduction Videos: https://goo.gl/nfZAbK

MaRS Discovery District

Located in the heart of Canada’s largest and the world’s most diverse city, MaRS is uniquely placed to lead change. We bring together educators, researchers, social scientists, entrepreneurs and business experts under one roof. Founded by civic leaders, we have a mission that is equal parts public and private — an entrepreneurial venture designed to bridge the gap between what people need and what governments can provide.

Place Matters

Place Matters: Learn more about the high-impact companies we work with, our programs and key successes in our report.Read the report: Learn more about the high-impact companies we work with, our programs and key successes in our online report (also available in PDF format).

MaRS is more than a building, it’s building on MaRS co-founder Dr. John Evans’ vision for the future. Great minds may not think alike but they like each other’s company; a brilliant idea in isolation is not enough to create a real breakthrough.

MaRS is a leader in the trend toward urban innovation districts, which allow entrepreneurs access to corporations, investors, mentors, university institutions and labs to test their concepts. We are where inspiration meets realization.

Community Leader

Innovation doesn’t just happen. As the Toronto Discovery District’s commercialization hub, MaRS gives entrepreneurs what they need most: a home with access to networks and capital. This community keeps our most promising talent here, and supplies established businesses and institutions with a steady stream of creativity.

Partnerships

As a home to entrepreneurs and a bridge to the business world, MaRS helps companies bring breakthrough ideas to market and scale globally. Partnerships are key, and building our corporate network has been a priority.

We work with corporations willing to leverage their global reach to assist startups seeking footholds in foreign markets. Corporations, in turn, are embedding teams at MaRS to boost creativity, scout talent and rekindle their entrepreneurial flames.

Venture Services

Entrepreneurs are a sociable bunch; they enjoy interaction as well as transaction. A chance to meet like-minded individuals is a major reason startups join MaRS Venture Services, whose main goal, of course, is to help them accelerate by providing expert advice, market intelligence and access to capital, as well as connections to talent and customers.

Impact

MaRS is not just about creating billion-dollar companies, but touching a billion lives. We are creating a vanguard of entrepreneurs working to improve society for future generations and making a difference beyond our borders.

Ella Korets-Smith
Ella Korets-Smith
LinkedIn logo
BIO

Ella Korets-Smith is Executive Director of TO Health! and Principal at EKS Business Development, an independent consulting firm passionate about creating value for Canadian biotech and medical device companies through building strong relationships. In her 10 years in industry, Ella worked with small and large, public and private life science and medical device companies, holding positions such as Director Business Development and Director Market Development with a track record of closing deals and leading successful marketing and business development programs. Examples of her accomplishments include in-licensing a new product from Merck KGaA into Immunovaccine’s portfolio, allowing the company to raise over $7 million in financing, plan and implement Nordion’s market expansion plan including Gamma Centre of Excellence, a premier research facility focused on growing the gamma market, and completing a market entry strategy for Synergy Health, a large publicly-traded company, to support the largest organic growth investment case in the company’s history. Ella has an extensive network in the GTA health sciences cluster and a growing network of international business leaders extends her reach to customers and partners in key markets in North America and around the world. Ella has an MSc in Medical Genetics from the University of Toronto and an MBA from Dalhousie University.

Massachusetts Life Sciences Center. United States

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences.

Mr. Angus McQullken
LinkedIn logo VP Communications & Marketing 
BIO

Angus McQuilken joined the Massachusetts Life Sciences Center (MLSC) in 2008, and he currently serves as Vice President for Communications & Marketing. In this capacity he oversees media relations, electronic communications, event coordination, trade shows and other marketing activities. McQuilken serves as a member of the MLSC’s senior management team, and he co-leads the Center’s business development efforts that have drawn dozens of new companies to Massachusetts. Prior to his work at the MLSC, Angus served as Vice President for Public Affairs for Planned Parenthood League of Massachusetts, as Deputy Communications Director for the Democratic National Convention Committee, and as Chief of Staff for State Senator Cheryl Jacques. He currently serves as an adjunct instructor in the Communication Department at Lasell College in Newton, Massachusetts. Angus holds a BA in political science from the University of Massachusetts Amherst. In 2008 he received the Distinguished Citizen Award from the Massachusetts chapter of the American Society for Public Administration. He enjoys basketball, long-distance bicycling and politics.

Ontario Bioscience Innovation Organization (OBIO) Canada

OBIO, a not-for-profit, membership-based organization engaged in the development of and integrated health innovation economy for Ontario that will become a leader in providing health technology to the internatoinal marketplace. A key initiative is the OBIO Capital Access Advisory Programs (CAAP).  Led by OBIO and a North American Steering Committee including senior venture capitalists and seasoned entrepreneurs from MedImmune Ventures, Johns Hopkins, J&J, Genesys Capital, Lumira Capital, BDC Capital and Versant Ventures, we work with high-potential CAAP companies including those devloping therapeutics, med device, diagnostics and HIT products and services.

Gail Garland
CEO